NVIDIA
NVDA
Tesla
TSLA
Taiwan Semiconductor
TSM
4
Palantir
PLTR
5
Super Micro Computer
SMCI
US Stock MarketDetailed Quotes
CANF Can-Fite BioPharma
- 1.6200
- -0.1000-5.81%
Close Mar 4 16:00 ET
- 1.6200
- 0.00000.00%
Post 18:25 ET
9.88MMarket Cap-0.62P/E (TTM)
1.7000High1.5401Low145.21KVolume1.7000Open1.7200Pre Close233.58KTurnover2.38%Turnover RatioLossP/E (Static)6.10MShares4.690052wk High3.98P/B9.87MFloat Cap1.290052wk Low--Dividend TTM6.10MShs Float1419.0000Historical High--Div YieldTTM9.30%Amplitude1.2900Historical Low1.6080Avg Price1Lot Size
Can-Fite BioPharma Stock Forum
While some caught my eye early, there are others I've just recently become aware of.
Many Oz companies can grow, produce and distribute overseas... quite a lot of international companies base growing/distribution operations in Europe, some can produce or grow here but only distribute their products overseas.. some are able to produce, grow, develop and distribute do...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY...
The clinical results from Can-Fite's Namodenoson represent a potentially significant breakthrough in the treatment of decompensated liver cirrhosis. The observed improvements in multiple key disease markers are particularly noteworthy:
Resolution of moderate ascites and elimination of diuretic dependency, indicating improved liver function and portal hypertension management
Cessation of gastrointestinal bleeding episodes, sugg...
Liver Cirrhosis Breakthrough: Patient's Remarkable Recovery Sparks Hope for 10.6M Sufferers
Can-Fite BioPharma's Namodenoson Shows Potential To Stabilize Advanced Liver Cirrhosis, Offering New Hope Amid Limited Treatment Options
Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson
Tuesday, 18th February at 7:00 am
Liver cirrhosis treatment market is estimated to reach approximately $15 billion in the U.S. by 2030
Ramat Gan, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseas...
When and where will Can-Fite BioPharma (CANF) present at the BIO CEO Conference 2025?
Can-Fite BioPharma will present on February 10, 2025, at 3:45 pm EST at the New York Marriott Marquis in New York City.
What clinical trials is CANF currently conducting with Namodenoson?
Namodenoson is currently in a pivotal Phase III trial for advanced liver cancer and a Phas...
No comment yet